Classes
DEA Class; Rx
Common Brand Names; Luminal
- Anticonvulsants, Barbiturates
Description
Oral and parenteral anticonvulsant and sedative-hypnotic; longest acting barbiturate; effective in all seizure disorders except absence (petit mal); also used for neonatal withdrawal syndrome; close monitoring for emerging or worsening suicidal thoughts/behavior or depression is recommended.
Indications
Typically used after benzodiazepines and phenytoin fail to abort status epilepticus
All types of seizure disorders, including partial, tonic-clonic, and myoclonic seizures
For the maintenance treatment of all types of seizures, including but not limited to partial seizures, myoclonic seizures, tonic-clonic seizures, or neonatal seizures not responding to other anticonvulsants.
Contraindications
Hypersensitivity
Porphyria
Intra-arterial or subcutaneous administration
Severe hepatic impairment
Dyspnea or airway obstruction
History of sedative hyponotic addiction
Nephritic patients (large doses)
Pregnancy/lactation
Adverse Effects
IV
Respiratory depression
Common
Ataxia
Dizziness
Drowsiness
Dysarthria
Fatigue
Headache
Irritability
Nystagmus
Paresthesia restlessness
Vertigo
Geriatric patients: Excitement, confusion, depression
Pediatric patients: Paradoxical excitement/hyperactivity
Less Common
Mental dullness
Constipation
Diarrhea
Nausea
Vomiting
Megaloblastic (folate-deficiency) anemia
Uncommon
Rash
Hypocalcemia
Hepatotoxicity
Rare
Stevens-Johnson syndrome
Rickets
Osteomalacia
Warnings
Commercial injection is highly alkaline and may cause tissue necrosis if given SC or if it extravasates (if happens, treat with application of moist heat and injection of 0.5% procaine)
May render oral contraceptives ineffective
Paradoxical responses may occur, especially in pediatric patients and patients experiencing acute or chronic pain
May cause CNS depression, causing physical and mental impairment; caution patient about performing tasks that require mental alertness
May cause respiratory depression, especially with intravenous administration; use caution in patients with respiratory disease and status asthmaticus
Withdraw therapy gradually; abrupt discontinuation, may increase seizure frequency
Use caution in patients with severe anemia, patients experiencing depression, cardiac disease, hemodynamically unstable patients, hyperthyroidism, renal impairment, hypoadrenalism, and in patients with diabetes
May mask important symptoms when used in patients with acute or chronic pain; use caution
Pregnancy and Lactation
Pregnancy category: D
Lactation: Do not nurse
Maximum Dosage
Specific maximum dosage information not available; individualize dosage based on monitoring of serum phenobarbital concentrations and clinical parameters. 200 mg/day PO is a general estimation for outpatient chronic use.
Specific maximum dosage information not available; individualize dosage based on monitoring of serum phenobarbital concentrations and clinical parameters. 200 mg/day PO is a general estimation for outpatient chronic use.
Specific maximum dosage information not available; individualize dosage based on monitoring of serum phenobarbital concentrations and clinical parameters. For status epilepticus, single doses do not usually exceed 20 mg/kg IV (Max: 1,000 mg/dose); for anticonvulsant maintenance treatment, doses above 6 mg/kg/day are not usually necessary.
Specific maximum dosage information not available; individualize dosage based on monitoring of serum phenobarbital concentrations and clinical parameters. For status epilepticus, single doses do not usually exceed 20 mg/kg IV (Max: 1,000 mg/dose); for anticonvulsant maintenance treatment, doses above 8 (7 years and older) to 10 mg/kg/day (6 years and younger) are not usually necessary.
Specific maximum dosage information not available; individualize dosage based on monitoring of serum phenobarbital concentrations and clinical parameters. For status epilepticus, single doses do not usually exceed 20 mg/kg IV; for anticonvulsant maintenance treatment, doses above 10 mg/kg/day are not usually necessary.
Specific maximum dosage information not available; individualize dosage based on monitoring of serum phenobarbital concentrations and clinical parameters. For status epilepticus, single doses do not usually exceed 20 mg/kg IV; for anticonvulsant maintenance treatment, doses above 5 mg/kg/day are not usually necessary.
How supplied
Phenobarbital
tablet: Schedule IV
15mg
16.2mg
30mg
32.4mg
60mg
64.8mg
97.2
100mg
elixir: Schedule IV
20mg/5mL
injectable solution: Schedule IV
65mg/mL
130mg/mL